When does the Crysvita “patent cliff” happen?
Crysvita (burosumab) is protected by a mix of patents and exclusivities that can expire in different years, which is why the term “patent cliff” usually refers to multiple layers of protection falling away rather than a single date.
The exact timing depends on:
- Which country you care about (US vs EU vs UK vs Japan can differ)
- Whether you mean patent expiration specifically or broader market exclusivity/paediatric or biologic exclusivity rules
- The specific patents (process, formulation, use, dosing, specific targets/claims), which do not all expire together
Because the question is time-specific, you’ll usually need a jurisdiction + patent number list to determine the real cliff date.
What happens when patents expire for Crysvita?
When Crysvita’s relevant protections expire, biosimilar or follow-on biologic developers can potentially seek approval and enter the market, depending on:
- Regulatory pathway timing in that country
- Whether any additional “evergreening” patents still cover specific aspects of the product
- Whether litigation or regulatory stays delay approval or launch
That market entry risk is the practical meaning of a “patent cliff” for investors and payers: even if manufacturing continues, pricing pressure can start once competitors can launch.
Are there biosimilars of Crysvita already (or planned)?
Competition would generally come from biosimilar versions of burosumab, but which products exist and when they may launch depends on:
- Patent status in each jurisdiction
- Regulatory review timelines and any legal delays
- Whether companies have credible clinical/analytical comparability packages for a biologic like burosumab
If you share the country (for example, US) and whether you’re asking about “first potential approval date” versus “commercial launch,” I can narrow the answer to the right framework.
Why is the “cliff” complicated for biologics like Crysvita?
For biologics, the market can stay protected longer than a single headline patent suggests because protection can be split across:
- Multiple patents with staggered expiries
- Separate claim scopes (not every patent covers the same “thing”)
- Litigation that can pause biosimilar approvals or launches
- Non-patent exclusivities that can still block competitors
So “patent cliff” often shows up as a gradual decline in exclusivity coverage rather than an overnight drop.
How can you estimate a patent cliff date if you don’t have the full patent list?
A common approach is to:
- Identify the latest-expiring relevant patents for the product (and key claim types)
- Add any regulatory exclusivity that applies in that jurisdiction
- Note known litigation that could change effective timing
If you tell me the jurisdiction (US/EU/UK/etc.) and whether you want the answer for “patent expiry” or “expected biosimilar entry,” I can help structure the calculation and what to look up.
What to check for Crysvita specifically
To pin down Crysvita’s patent cliff, check these categories for your jurisdiction:
- Product and composition patents tied to burosumab
- Method-of-treatment or dosing regimen patents
- Process/purification patents
- Any “regulatory exclusivity” (including biologic-related exclusivity rules)
- Known lawsuits involving biosimilar applicants
What I need from you to give the exact cliff timing
Right now, your question doesn’t specify country or the protection type. Reply with:
1) Which market: US, EU, UK, Japan, or “global”
2) Whether you mean: patent expiration date(s) or expected biosimilar launch window
3) If you have a particular patent number/patent list you’re looking at, paste it
Then I can produce a precise, date-oriented “Crysvita patent cliff” answer for that scope.